During the last session, 2seventy bio Inc (NASDAQ:TSVT)’s traded shares were 0.42 million, with the beta value of the company hitting 1.77. At the end of the trading day, the stock’s price was $2.91, reflecting an intraday loss of -1.69% or -$0.05. The 52-week high for the TSVT share is $6.40, that puts it down -119.93 from that peak though still a striking 4.47% gain since the share price plummeted to a 52-week low of $2.78. The company’s market capitalization is $150.12M, and the average intraday trading volume over the past 10 days was 0.54 million shares, and the average trade volume was 319.85K shares over the past three months.
2seventy bio Inc (TSVT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.60. TSVT has a Sell rating from 1 analyst(s) out of 7 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
2seventy bio Inc (NASDAQ:TSVT) trade information
2seventy bio Inc (TSVT) registered a -1.69% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.69% in intraday trading to $2.91, hitting a weekly high. The stock’s 5-day price performance is -4.90%, and it has moved by -23.02% in 30 days. Based on these gigs, the overall price performance for the year is -24.22%. The short interest in 2seventy bio Inc (NASDAQ:TSVT) is 4.68 million shares and it means that shorts have 16.97 day(s) to cover.
The consensus price target of analysts on Wall Street is $2, which implies a decrease of -45.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2 respectively. As a result, TSVT is trading at a premium of 31.27% off the target high and 31.27% off the low.
2seventy bio Inc (TSVT) estimates and forecasts
Statistics show that 2seventy bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. 2seventy bio Inc (TSVT) shares have gone down -27.79% during the last six months, with a year-to-date growth rate more than the industry average at 78.96% against 16.80.
While earnings are projected to return 81.88% in 2025.
TSVT Dividends
2seventy bio Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
2seventy bio Inc (NASDAQ:TSVT)’s Major holders
2seventy bio Inc insiders own 4.05% of total outstanding shares while institutional holders control 90.41%, with the float percentage being 94.22%. KYNAM CAPITAL MANAGEMENT, LP is the largest shareholder of the company, while 156.0 institutions own stock in it. As of 2024-06-30, the company held over 5.95 million shares (or 11.4341% of all shares), a total value of $22.92 million in shares.
The next largest institutional holding, with 4.14 million shares, is of GOLDMAN SACHS GROUP INC’s that is approximately 7.9465% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $15.93 million.
